Peptide deformylase inhibitors: a survey of the patent literature

Bibliography

• HIRAMATSU K, HANAKI H, INO T, YABUTA K, OGURI T, TENOVER FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. (1997) 40(1):135–136.
   PubMed Web of Science ®Google Scholar
• MILLER D, URDANETA WELTMAN A, PARKS: Vancomycin-resistant Staphylococcus aureus — Pennsylvania 2002. Morb. Mort. Weekly Rep. (2002) 52:902.
   Google Scholar
• D'AGATA EM: Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect. Control Hosp. Epidemiol. (2004) 25(10):842–846.
   PubMedGoogle Scholar
• STREIT JM, JONES RN, SADER HS, FRITSCHE TR: Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents (2004) 24(2):111–118.
   PubMed Web of Science ®Google Scholar
• HEROLD BC, IMMERGLUCK LC, MARANAN MC et al.: Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. J. Am. Med. Ass. (1998) 279(8):593–598.
   PubMed Web of Science ®Google Scholar
• •Description of the first occurances of community aquired methicillin-resistant S. aureus.
   Google Scholar
• FRIDKIN SK, HAGEMAN JC, MORRISON Met al.: Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl. J. Med. (2005) 352(14):1436–1444.
   Google Scholar
• MILLER LG, PERDREAU -REMINGTON F, RIEG G et al.: Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl. J. Med. (2005) 352(14):1445–1453.
   PubMedGoogle Scholar
• LIVERMORE DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. (2002) 34(5):634–640.
   Google Scholar
• MAHGOUB S, AHMED J, GLATT AE: Completely resistant Acinetobacter baumannii strains. Infect. Control Hosp. Epidemiol (2002) 23(8):477–479.
   PubMedGoogle Scholar
• MCGOWAN JE JR, TENOVER FC: Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists. Nat. Rev. Microbiol (2004) 2(3):251–258.
   PubMedGoogle Scholar
• PROJAN S: New (and not so new) antibacterial targets - from where and when will the novel drugs come? Curr. Opin. Pharmacol (2002) 2(5):513–522.
   PubMedGoogle Scholar
• WALSH FM, AIVIYES SG: Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr. Opin. Microbiol (2004) 7(5):439–444.
   PubMedGoogle Scholar
• WOODFORD N: Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Cl. Microbiol Infect. (2005) 11(3):S2–S21.
   Google Scholar
• KIM 0, FUNG-TOMC J: Patents on 0-lactams antibacterials. Expert Opin.Ther. Targets (2001) 11:1267–1276.
   Google Scholar
• KUMAR S, PEARSON AL, PRATT RF: Design, synthesis, and evaluation of a-ketoheterocycles as class C 0-lactamase inhibitors. Bioorg. Med Chem. (2001) 9(8):2035–2044.
   PubMedGoogle Scholar
• COATES A, HU Y, BAX R, PAGE C: The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug. Discov. (2002) 1(11):895–910.
   PubMed Web of Science ®Google Scholar
• ••Good overview, together with [17,18], ofscientific and regulatory problems regarding the development and marketing of anti-infectives.
   Google Scholar
• SHLAES DM: The abandonment of antibacterials: why and wherefore? Curr. Opin. Pharmacol (2003) 3(5):470–473.
   PubMed Web of Science ®Google Scholar
• THOMSON CJ, POWER E, RUEBSAMEN-WAIGMANN H, LABISCHINSKI H: Antibacterial research and development in the 21st century - an industry perspective of the challenges. Curr. Opin. Microbiol (2004) 7(5):445–450.
   PubMed Web of Science ®Google Scholar
• ALEKSHUN MN: New advances in antibiotic development and discovery. Expert Opin. Invest. Drugs (2005) 14(2):117–134.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of anti-infectivescurrently in development.
   Google Scholar
• BUSH K, MACIELAG M, WEIDNER -WELLS M: Taking inventory: antibacterial agents currently at or beyond Phase I. Curr. Opin. Microbiol (2004) 7(5):466–476.
   PubMed Web of Science ®Google Scholar
• RICE LB: Do we really need new anti-infective drugs? Curr. Opin. Pharmacol (2003) 3(5):459–463.
   PubMedGoogle Scholar
• WOODFORD N: Novel agents for the treatment of resistant Gram-positive infections. Expert Opin. Invest. Drugs (2003) 12(2):117–137.
   PubMed Web of Science ®Google Scholar
• SPELLBERG B, POWERS JH, BRASS EP, MILLER LG, EDWARDS JE JR: Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. (2004) 38(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• GIGLIONE C, PIERRE M, MEINNEL T: Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. MoL Microbiol (2000) 36(6):1197–1205.
   PubMedGoogle Scholar
• APFEL CM, LOCHER H, EVERS S et al: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45(4):1058–1064.
   PubMed Web of Science ®Google Scholar
• YUAN Z, TRIAS J, WHITE RJ: Deformylase as a novel antibacterial target. Drug Discov. Today (2001) 6(18):954–961.
   PubMed Web of Science ®Google Scholar
• CHEN DZ, PATEL DV HACKBARTH CJ et al.: Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry (2000) 39(6):1256–1262.
   Google Scholar
• ZHANG L, FAN F, PALMER LM et al: Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene (2000) 255(2):297–305.
   PubMedGoogle Scholar
• MEINNEL T, BLANQUET S: Characterization of the Thermus thermophilus locus encoding peptide deformylase and methionyl-tRNA(fMet) formyltransferase. J. Bact. (1994) 176(23):7387–7390.
   PubMedGoogle Scholar
• MARGOLIS P, HACKBARTH C, LOPEZ S et al: Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defi3. Antimicrob. Agents Chemother. (2001) 45(9):2432–2435.
   PubMedGoogle Scholar
• GIGLIONE C, BOULAROT A, MEINNEL T: Protein N-terminal methionine excision. Cell. Mol. Life Sci. CMLS (2004) 61(12):1455–1474.
   PubMedGoogle Scholar
• MEINNEL T: Peptide deformylase of eukaryotic protists: a target for new antiparasitic agents? Parasitol Today (2000) 16(4):165–168.
   PubMedGoogle Scholar
• GIGLIONE C, MEINNEL T: Peptide deformylase as an emerging target for antiparasitic agents. Emerging They. Targets (2001) 5(1):41–57.
   PubMedGoogle Scholar
• BOULAROT A, GIGLIONE C, ARTAUD I, MEINNEL T: Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors. Curr. Opin. Invest. Drugs (2004) 5(8):809–822.
   PubMedGoogle Scholar
• ••Comprehensive overview, together with [35], of peptide deformylase and its therapeutic potential.
   Google Scholar
• JOHNSON KW, LOFLAND D, MOSER HE: PDF inhibitors: an emerging class of antibacterial drugs. Curr. Drug Targets Infect. Disord. (2005) 5(1):39–52.
   PubMedGoogle Scholar
• JAIN R, CHEN D, WHITE RJ, PATEL DV, YUAN Z: Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. (2005) 12:1607–1621.
   PubMedGoogle Scholar
• RAJAGOPALAN PTR, PEI D: Oxygen-mediated inactivation of peptide deformylase J. Biol. Chem. (1998) 273(35):22305–22310.
   Google Scholar
• KREUSCH A, SPRAGGON G, LEE CC et al.: Structure analysis of peptide deformylases from Streptococcus pneumoniae, Staphylococcus aureus, Thermotoga maritima and Pseudomonas aeruginosa: snapshots of the oxygen sensitivity of peptide deformylase. j Mo/. Bid. (2003) 330(2):309–321.
   PubMedGoogle Scholar
• CHAN MK, GONG W, RAJAGOPALAN PT, HAO B, TSAI CM, PEI D: Crystal structure of the Escherichia coli peptide deformylase. Biochemistry (1997) 36(45):13904–13909.
   PubMedGoogle Scholar
• BECKER A, SCHLICHTING I, KABSCH W, SCHULTZ S, VOLKER WAGNER AF: Structure of peptide deformylase and identification of the substrate binding site. J. Biol. Chem. (1998) 273(19):11413–11416.
   PubMedGoogle Scholar
• HAO B, GONG W, RAJAGOPALAN PT, ZHOU Y, PEI D, CHAN MK: Structural basis for the design of antibiotics targeting peptide deformylase. Biochemistry (1999) 38(15):4712–4719.
   PubMedGoogle Scholar
• CLEMENTS JM, BECKETT RP, BROWN A et al.: Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2001) 45(2):563–570.
   PubMedGoogle Scholar
• BALDWIN ET, HARRIS MS, YEM AW et al.: Crystal structure of Type II peptide deformylase from Staphylococcus aureus. Biol. Chem. (2002) 277(34):31163–31171.
   Google Scholar
• GUILLOTEAU J-P, MATHIEU M, GIGLIONE C et al.: The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. MoL Biol. (2002) 320(5):951–962.
   PubMedGoogle Scholar
• SMITH HK, BECKETT RP, CLEMENTS JM et al.: Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the metal binding group. Bioorg Med Chem. Lett. (2002) 12(24):3595–3599.
   PubMedGoogle Scholar
• HU X, NGUYEN KT, VERLINDE CLMJ, HOL WGJ, PEI D: Structure-based design of a macrocyclic inhibitor for peptide deformylase. J. Med. Chem. (2003) 46(18):3771–3774.
   PubMedGoogle Scholar
• SMITH KJ, PETIT CM, AUBART K et al.: Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Protein Science (2003) 12(2):349–360.
   PubMedGoogle Scholar
• HOWARD MH, CENIZAL T, GUTTERIDGE S et al.: A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening. J. Med. Chem. (2004) 47(27):6669–6672.
   PubMedGoogle Scholar
• MOLTENI V HEX, NABAKKA J et al.: Identification of novel potent bicyclic peptide deformylase inhibitors. Bioorg Med Chem. Lett. (2004) 14(0:1477–1481.
   PubMedGoogle Scholar
• ROBIEN MA, NGUYEN KT, KUMAR A et al. An improved crystal form of Plasmodium fafriparum peptide deformylase. Protein Science (2004) 13(4):1155–1163.
   PubMedGoogle Scholar
• ZHOU Z, SONG X, LI Y, GONG W: Unique structural characteristics of peptide deformylase from pathogenic bacterium Leptospira interrogans. J. MoL Biol. (2004) 339(1):207–215.
   PubMedGoogle Scholar
• BRACCHI-RICARD V, NGUYEN KT, ZHOU Y, RAJAGOPALAN PT, CHAKRABARTI D, PEI D: Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Biophys. (2001) 396(2):162–170.
   PubMed Web of Science ®Google Scholar
• GIGLIONE C, SERERO A, PIERRE M, BOISSON B, MEINNEL T: Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. Eur. MoL Biol. Org (2000) 19(21):5916–5929.
   PubMedGoogle Scholar
• SERERO A, GIGLIONE C, SARDINI A, MARTINEZ-SANZ J, MEINNEL T: An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway./ Biol. Chem. (2003) 278(52):52953–52963.
   Google Scholar
• NGUYEN KT, HU X, COLTON C, CHAKRABARTI R, ZHU MX, PEI D: Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry (2003) 42(33):9952–9958.
   PubMedGoogle Scholar
• RAMANATHAN-GIRISH S, MCCOLM J, CLEMENTS JM et al.: Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob. Agents Chemother. (2004) 48(12):4835–4842.
   PubMed Web of Science ®Google Scholar
• GORDON JJ, KELLY BK, MILLER GA: Actinonin: an antibiotic substance produced by actinomycete. Nature (1962) 195:701–702.
   PubMed Web of Science ®Google Scholar
• DAVIES SJ, AYSCOUGH AP, BECKETT RP et al.: Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2' and P3' side chains. Bioorg Med Chem. Lett. (2003) 13(16):2715–2718.
   PubMedGoogle Scholar
• EAST SP, BECKETT RP, BROOKINGS DC et al.: Peptide deformylase inhibitors with activity against respiratory tract pathogens. Bioorg Med Chem. Lett. (2004) 14(1):59–62.
   PubMedGoogle Scholar
• WISE R, ANDREWS JM, ASHBY J: In vitro activities of peptide deformylase inhibitors against Gram-positive pathogens. Antimicrob. Agents Chemother. (2002) 46(4):1117–1118.
   PubMed Web of Science ®Google Scholar
• LOFLAND D, DIFUNTORUM S, WALLER A et al.: In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. (2004) 53(4):664–668.
   PubMed Web of Science ®Google Scholar
• BOWKER KE, NOEL AR, MACGOWAN AP: In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int. j Antimicrob. Agents (2003) 22(6):557–561.
   PubMedGoogle Scholar
• GROSS M, CLEMENTS J, BECKETT RP et al.: Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. J . Antimicrob. Chemother. (2004) 53(3):487–493.
   PubMedGoogle Scholar
• HUNTINGTON KM, YT T, WEI Y, PEI D: Synthesis and antibacterial activity of peptide deformylase inhibitors. Biochemistry (2000) 39(15):4543–4551.
   PubMedGoogle Scholar
• LOPEZ S, WU C, BLAIS J et al.: In vitro profiling of the new peptide deformylase inhibitor LBM415. 44th Annual InterScience Conference on Microbial Agents and Chemotherapy (ICAAC), Abst Washington DC, USA (2004).
   Google Scholar
• JONES RN, FRITSCHE TR, SADERA HS: Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates. Diagn. MicrobioL DU . (2004) 49(1):63–65.
   PubMedGoogle Scholar
• JONES RN, MOET GJ, SADER HS, FRITSCHE TR: Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J. Antimicrob. Chemother. (2004) 53(5):804–807.
   PubMed Web of Science ®Google Scholar
• JONES RN, SADER HS, FRITSCHE TR: Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). Diagn. MicrobioL Infect. Dis. (2005) 51(2):139–141.
   PubMedGoogle Scholar
• CREDITO K, LIN G, EDNIE LM, APPELBAUM PC: Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. (2004) 48(10):4033–4036.
   PubMed Web of Science ®Google Scholar
• EDNIE LM, PANKUCH G, APPELBAUM PC: Antipneumococcal activity of LBM415, a new peptide diformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. (2004) 48(10):4027–4032.
   PubMed Web of Science ®Google Scholar
• WAITES KB, CRABB DM, DUFFY LB: Comparative in vitro activities of an investigational peptide deformylase inhibitor LBM415 and other agents against mycoplasmas and ureaplasmas of human origin. 44th Annual InterScience Conference on Microbial Agents and Chemotherapy (ICAAC), Abst E-2050. Washington DC, USA (2004).
   Google Scholar
• BELL JM, TURNIDGE JD, INOUE M et al.: Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. Antimicrob . Chemother. (2005) 55 (2): 276–278.
   Google Scholar
• FRITSCHE TR., SADER HS, CLEELAND R, JONES RN: Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob. Agents Chemother. (2005) 49(4):1468–1476.
   PubMedGoogle Scholar
• RYDER NS, DZINK-FOX J, KUBIK B et al.: LBM415, a new peptide deformylase inhibitor with potent in vitro activity against drug-resistant bacteria. 44th Annual InterScience Conference on Microbial Agents and Chemotherapy (ICAAC), Abst F-I956 Washington DC, USA (2004).
   Google Scholar
• OSBORNE CS, NECKERMANN G, GOLDOVITZ J et al.: Pharmacodynamics of LBM-415, a new peptide deformylase inhibitor, in the neurotropic mouse thigh infection model. 44th Annual InterScience Conference on Microbial Agents and Chemotherapy (ICAAC), Abst F-1963. Washington DC, USA (2004).
   Google Scholar
• BRACKEN K: Peptide deformylase inhibitors. Superbugs and Superdrugs London, UK (2004).
   Google Scholar
• NECKERMANN G, YU D, MANNI K et al.: LBM415, a new oral peptide deformlyase inhibitor: efficacy in murine infection models. 44th Annual InterScience Conference on Microbial Agents and Chemotherapy (ICAAC), Abst. F-I964. Washington DC, USA (2004).
   Google Scholar
• FONSECA-ATEN M, RIOS AM, MEJIAS A et al.: Evaluation of NVP-PDF713 for the treatment of experimental Mycoplasma pneumoniae pneumonia. 44th Annual InterScience Conference on Microbial Agents and Chemotherapy (ICAAC), Washington DC, USA (2004) Abst. F–1966.
   Google Scholar
• GEORGOPAPADAKOU N: Superbugs superdrugs: a focus on antibacterials. 6th Annual SMi Conference. Expert Opin. Emerg. Drugs (2004) 9(1):191–195.
   Google Scholar
• HU X, NGUYEN KT, JIANG VC, LOFLAND D, MOSER HE, PEI D: Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size. J. Med. Chem. (2004) 47(20):4941–4949.
   PubMedGoogle Scholar
• TAMAKI K, KURIHARA S, OIKAWA T, TANZAWAK, SUGIMURAY: Matylstatins, new inhibitors of Type II collagenases from Aciinomadura atramentaria.W. Synthesis and structure-activity relationships of matylstatin B and its stereoisomers. J. Antibiot (1994) 47(12):1481–1492.
   Google Scholar
• THORARENSEN A, DEIBEL MR JR, ROHRER DC et al.: Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. [Erratum to document cited in CA135:235893]. Bioorg. Med Chem. Lett. (2001) 11(15):2053.
   Google Scholar
• HEALTH RJ, LI J, ROLAND GE, ROCK CO: Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biological Chemistry (2000) 275:4654–4659.
   PubMedGoogle Scholar
• MCDEVITT D, ROSENBERG M: Exploiting genomics to discover new antibiotics. Trends MicrobioL (2001) 9(12):611–617.
   PubMed Web of Science ®Google Scholar
• MCDEVITT D, PAYNE DJ, HOLMES DJ, ROSENBERG M: Novel targets for the future development of antibacterial agents. Symp. Series Soc. Appl. MicrobioL (2002) (31):285–345.
   Google Scholar
• READ TD, GILL SR, TETTELIN H, DOUGHERTY BA: Finding drug targets in microbial genomes. Drug Discov. Today (2001) 6:887–892.
   PubMedGoogle Scholar
• HUGHES D: Exploiting genomics, genetics and chemistry to combat antibiotic resistance. Nat. Rev. Gen. (2003) 4(6):432–441.
   PubMedGoogle Scholar
• HACKBARTH CJ, CHEN DZ, LEWIS JG et al.: N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Anti microb. Agents Chemother. (2002) 46(9):2752–2764.
   PubMed Web of Science ®Google Scholar
• GIGLIONE C, MEINNEL T: Resistance to anti-peptide deformylase drugs. Expert Opin.Ther. Targets (2001) 5(3):415–418.
   PubMedGoogle Scholar
• MARGOLIS PS, HACKBARTH CJ, YOUNG DC et al.: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. (2000) 44(7):1825–1831.
   PubMed Web of Science ®Google Scholar
• DEAN CR, NARAYAN S, DAIGLE DM et al.: Role of the AcrAB-To1C efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob. Agents Chemother. (2005) 49(8):3129–3135.
   PubMedGoogle Scholar
• AZOULAY-DUPUIS E, MOHLER J, BEDOS JP: Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob. Agents Chemother. (2004) 48(1):80–85.
   PubMedGoogle Scholar